
Opinion|Videos|March 25, 2025
Adverse Events Monitoring and Management in BPDCN Treatment
Author(s)Marlise R. Luskin, MD, MSCE
An expert discusses how monitoring capillary leakage syndrome (CLS) requires vigilant assessment of fluid balance, hemodynamics, and biomarkers. Academic settings may have advanced resources, whereas community settings rely on standardized protocols. Key adverse effects include hypotension, edema, and organ dysfunction. Management includes fluid resuscitation, vasopressors, and close monitoring.
Advertisement
Video content above is prompted by the following:
- What protocols/strategies do you implement to monitor CLS?
- What are specific considerations (ie, academic vs community setting)?
- What other adverse effects are critical to monitor?
- What strategies can be implemented to mitigate/manage them?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
5



















